Investor Overview

Corporate Profile

Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform which is utilized to discover and develop novel peptide-based drugs to address significant unmet medical needs. Its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by market... Read more

Stock Quote

PTGX (Common Stock)
$19.61 + 0.52 (2.72%)
Exchange :NASDAQ
Volume :89,244
Today's Open$19.20
Previous Close$19.09
Data as of November 22, 2017 4:00 p.m. ET
Refresh quote

Stock Chart

Stock chart for: PTGX.O.  Currently trading at $19.61 with a 52 week high of $26.36 and a 52 week low of $8.00.

Recent Press Releases

November 09, 2017

Protagonist Therapeutics Initiates Phase 1 Trial of Oral Peptide IL-23 Receptor Antagonist, PTG-200 read more

November 06, 2017

Protagonist Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update read more

November 01, 2017

Protagonist Therapeutics to Present at the Stifel 2017 Healthcare Conference read more

Upcoming Events

There are currently no events scheduled.


Investor Presentation

Data provided by Nasdaq. Minimum 15 minutes delayed.